Share on StockTwits

IDEXX Laboratories (NASDAQ:IDXX) Director M Anne Szostak bought 2,000 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, August 13th. The shares were purchased at an average cost of $127.03 per share, for a total transaction of $254,060.00. Following the completion of the purchase, the director now directly owns 7,000 shares of the company’s stock, valued at approximately $889,210. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on IDXX shares. Analysts at Piper Jaffray raised their price target on shares of IDEXX Laboratories from $125.00 to $126.00 in a research note on Monday, July 28th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of IDEXX Laboratories in a research note on Wednesday, July 16th. They now have a $139.00 price target on the stock. Finally, analysts at Canaccord Genuity upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, June 24th. They now have a $148.00 price target on the stock, up previously from $116.00. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $136.60.

IDEXX Laboratories (NASDAQ:IDXX) traded down 0.73% on Thursday, hitting $126.65. 179,007 shares of the company’s stock traded hands. IDEXX Laboratories has a 1-year low of $92.09 and a 1-year high of $140.00. The stock’s 50-day moving average is $130.8 and its 200-day moving average is $126.. The company has a market cap of $6.367 billion and a P/E ratio of 34.81.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings data on Friday, July 25th. The company reported $1.10 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.05 by $0.05. The company had revenue of $390.00 million for the quarter, compared to the consensus estimate of $385.20 million. During the same quarter in the prior year, the company posted $0.99 earnings per share. The company’s quarterly revenue was up 10.6% on a year-over-year basis. Analysts expect that IDEXX Laboratories will post $3.70 EPS for the current fiscal year.

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets.

Receive News & Ratings for IDEXX Laboratories Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.